Monitor for updates on the registrational myositis trial data in mid-2027 and initiation of the SSc-ILD cohort in 4Q26. The cash runway into mid-2027 provides a buffer, but with no near-term catalysts, the stock is likely to trade on pipeline sentiment and broader biotech sector trends.
Price Chart
Executive Summary
Cabaletta Bio reported Q2 2026 EPS of -$0.34, beating consensus of -$0.37 by 8.1%, with no revenue. The company highlighted progress in its registrational myositis trial (data mid-2027, BLA 2H27) and plans to initiate a second registrational cohort in SSc-ILD in 4Q26. Cash position strengthened to $225.1M post a $150M May offering, extending runway into mid-2027, but the EPS beat is modest and pipeline milestones remain distant, making this a neutral event.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.34 beat consensus of -$0.37 by 8.1%
- Cash, cash equivalents, and short-term investments were $225.1M as of June 30, 2026, up from $133.6M at year-end 2025
- Registrational RESET-Myositis data expected mid-2027 with BLA submission in 2H27
- SSc-associated ILD registrational cohort of ~25 patients expected to initiate in 4Q26
- PC-free approach being incorporated into RESET-MG trial
- ElevateBio selected as second CDMO for clinical and commercial manufacturing
Financial Impact
EPS beat of $0.03 (8.1%) vs consensus; cash position increased by $91.5M from year-end 2025 to $225.1M
Risk Factors
- Clinical trial failure or delay in myositis or SSc-ILD programs
- Cash burn rate may require additional financing before mid-2027 if milestones slip
- Competition from other CAR-T therapies in autoimmune diseases
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344398 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.91 (−34.36%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.91 (−33.91%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $1.91 (−36.54%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $1.91 (−46.65%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $1.91 (−47.96%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $1.91 (+47.09%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access